Spexis (formerly Polyphor) said that a Phase 1 study of inhaled murepavadin, which the company is developing for the treatment of P. aeruginosa lung infections, demonstrated that the inhaled formulation delivered via the PARI eFlow nebulizer was well tolerated at all dose levels and that concentrations of murepavadin in the lungs reached the desired levels while … [Read more...] about Spexis reports results from Phase 1 trial of inhaled murepavadin
News
Liquidia announces financing agreement for up to $100 million
Liquidia Corporation said that an investment by HealthCare Royalty (HCRx) of up to $100 million will support further clinical development and the potential launch of the company's Yutrepia treprostinil DPI. In return, HCRx will get tiered royalties on potential net revenue from Yutrepia and other Liquidia products in addition to fixed payments from Liquidia, with … [Read more...] about Liquidia announces financing agreement for up to $100 million
TFF Pharmaceuticals names Zamaneh Mikhak as Chief Medical Officer
TFF Pharmaceuticals, which is developing dry powder inhaled and nasal formulations based on its thin film freezing particle engineering technology, has announced the appointment of Zamaneh Mikhak as Chief Medical Officer. Mikhak was most recently Senior VP and Head of Clinical Development at Cogent Biosciences, and her prior industry experience includes roles at … [Read more...] about TFF Pharmaceuticals names Zamaneh Mikhak as Chief Medical Officer
ENA Respiratory gets $4.38 million from US Department of Defense for development of dry powder intranasal formulation of INNA-051
The US Department of Defense Chemical and Biological Defense Program (CBDP) has awarded Australian pharma company ENA Respiratory $4.38 million for development of a dry powder formulation of the company's INNA-051 intranasal pegylated TLR2/6 agonist for protection against a wide range of respiratory viruses, ENA said. According to ENA, the 12-month project is expected … [Read more...] about ENA Respiratory gets $4.38 million from US Department of Defense for development of dry powder intranasal formulation of INNA-051
Lupin launches Difizma triple combination DPI in India
Lupin announced that it has launched its Difizma indacaterol / glycopyrronium / mometasone DPI in India for the treatment of inadequately controlled asthma. The company says that Difizma is the first fixed dose combination approved for the treatment of poorly controlled asthma by the Drug Controller General of India (DCGI). In 2022, Glenmark launched an indacaterol … [Read more...] about Lupin launches Difizma triple combination DPI in India
Acorda Therapeutics announces new supply agreement with Catalent for manufacture of Inbrija inhaled dry powder levodopa
Acorda Therapeutics announced that it has signed a new supply agreement with Catalent that reduces the amount of product that the company is required to buy annually from $18 million to $8.5 million for 2023 and $15.5 million for 2024. From 2025 on, the announcement says, Acorda will pay a fixed amount per capsule "based on the amount of Inbrija needed in the US and … [Read more...] about Acorda Therapeutics announces new supply agreement with Catalent for manufacture of Inbrija inhaled dry powder levodopa
BiondVax reports positive preclinical results for its NanoAb inhaled nanosized antibodies against COVID-19
BiondVax Pharmaceuticals announced that 6 days post infection, hamsters treated with the company's NanoAb inhaled nanosized antibodies had levels of SARS-COV-2 in their lungs reduced to levels 30 times lower than hamsters that got an inhaled placebo. BiondVax licensed the NanoAb technology from the Max Planck Institute in March 2022 and announced development plans for … [Read more...] about BiondVax reports positive preclinical results for its NanoAb inhaled nanosized antibodies against COVID-19
James Noble named Pneumagen Chairman of the Board
Inhaled antiviral developer Pneumagen has announced the appointment of Adaptimmune Therapeutics founder James Noble as non-executive Chairman of the company's board of directors. Noble also co-founded Immunocore and serves as Chairman of Sutura Therapeutics, Celleron, and Orexo. In August 2022, Pneumagen initiated a Phase 2 challenge study of its Neumifil … [Read more...] about James Noble named Pneumagen Chairman of the Board
Pulmatrix reports Phase 1 results for PUR3100 inhaled dry powder DHE
Pulmatrix has announced that a Phase 1 PK trial of its PUR3100 dihydroergotamine (DHE) DPI in healthy volunteers demonstrated that all 3 doses tested produced peak exposures in the desired range with a Tmax of 5 minutes post-dose. Subjects receiving PUR3100 also experienced less nausea than those getting IV DHE. Pulmatrix, which is developing PUR3100 for the treatment … [Read more...] about Pulmatrix reports Phase 1 results for PUR3100 inhaled dry powder DHE
Copley Scientific names new Managing Director and Head of Business Development
Copley Scientific has announced the appointments of Jamie Clayton as Managing Director and Matthew Fenn as Head of Business Development. Clayton joined powder characterization specialist Freeman Technology in 2008 and then served as Freeman's Operations Director beginning in 2011. Fenn has extensive experience in inhaled drug delivery and was most recently Senior … [Read more...] about Copley Scientific names new Managing Director and Head of Business Development